PlainPharmaWatch

CMS Open Payments · Program Year 2024

Astellas Pharma US Inc

Astellas Pharma US Inc reported $10,615,634.48 in payments to 147,377 physicians and teaching hospitals across 147,377 transactions.

See the rankings → How this is sourced
$10.6M
Total payments
147,377
Transactions
147,377
Recipients
+$770.1K
General Payments vs PY2023

Astellas Pharma US Inc reported $10,615,634.48 in payments to 147,377 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #165 of 1,925 reporting manufacturers (0.1% of all US industry payments), averaging $72.03 per recipient across 7 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Astellas Pharma US Inc pairs top-10% payment volume with an unusually diversified payment pattern across a wide recipient base.

#165
of 1,925 companies
0.1%
of all US industry payments
0.1%
paid to its single top recipient
7
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Astellas Pharma US Inc's CMS-reported General Payments increased by $770.1K (+7.8%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: ASTELLAS PHARMA US INCPY2023: ASTELLAS PHARMA US INCPY2024: Astellas Pharma US Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$9.8MPY2024$10.6M
PY2023
$9,845,534.13
PY2024
$10,615,634.48

How Astellas Pharma US Inc ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Astellas Pharma US Inc's total vs. every reporting company

CMS Open Payments, Program Year 2024

$10,615,634 Top 9% higher than 91% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). Below this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Below this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). This entry sits in this band. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Astellas Pharma US Inc

$10,615,634.48: that is what Astellas Pharma US Inc reported in payments to 147,377 physicians and teaching hospitals during Program Year 2024, spread across 147,377 transactions ($72.03 per transaction, $72.03 per recipient). The company sits at rank #165 of 1,925, a comparatively small 0.1% slice of all industry payments reported nationwide for the year.

"Compensation for Services Other Than Consulting" leads the 7-category general-payment breakdown below at $4.0M (37.7% of the company's reported total, 1,451 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Across 7 types of general payments, Astellas Pharma US Inc's largest category was "Compensation for Services Other Than Consulting" at $4.0M - 37.7% of the company's reported total.

How Astellas Pharma US Inc divides its payments

How the reported total splits across payment categories

1. Compensation for Services…$4.0M2. Food and Beverage$3.4M3. Consulting Fee$1.8M4. Education$672.3K5. Travel and Lodging$622.2K6. Grant$136.2K7. Space Rental or Facility …$7.8K
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $4.0M 1,451
Food and Beverage $3.4M 135,988
Consulting Fee $1.8M 243
Education $672.3K 7,960
Travel and Lodging $622.2K 1,677
Grant $136.2K 55
Space Rental or Facility Fees $7.8K 3

Recipient Concentration in General Payments

The five largest recipient relationships account for $1,221,821.75 (11.5%) of $10,615,634.48 in this company's General Payments records across 60,722 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Astellas Pharma US Inc

The five named recipients with the highest reported General Payments from this company

Jennifer Ashton$876.9KPeter Kaiser$105.0KSeenu Hariprasad$83.8KScott Sellinger$80.1KStephen Freedland$76.0K
  1. 1

    Jennifer Ashton

    $876,910.80 across 6 reported transactions

  2. 2

    Peter Kaiser

    $105,000.00 across 2 reported transactions

  3. 3

    Seenu Hariprasad

    $83,803.01 across 62 reported transactions

  4. 4

    Scott Sellinger

    $80,106.26 across 64 reported transactions

  5. 5

    Stephen Freedland

    $76,001.68 across 43 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $72.03. Average per recipient: $72.03.

Total Amount

$10,615,634.48

Avg per Transaction

$72.03

Avg per Recipient

$72.03

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Astellas Pharma US Inc Share

0.1%

#165 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Astellas Pharma US Inc

Lexicon Pharmaceuticals, Inc.

$10.7M 20,498 recipients

Sanofi-Aventis U.s. LLC

$10.7M 42,061 recipients

Ortho-Clinical Diagnostics, Inc.

$10.7M 232 recipients

Treace Medical Concepts, Inc.

$10.5M 10,486 recipients

TG Therapeutics, Inc.

$10.7M 12,185 recipients

Alafair Biosciences, Inc.

$10.8M 704 recipients

Frequently Asked Questions

How much did Astellas Pharma US Inc pay to physicians and hospitals in 2024? ▾
In Program Year 2024, CMS Open Payments recorded $10,615,634.48 from Astellas Pharma US Inc to physicians and hospitals across 147,377 transactions - 0.1% of all industry payments reported that year.
How many physicians received payments from Astellas Pharma US Inc? ▾
147,377 physicians and teaching hospitals received payments from Astellas Pharma US Inc in 2024, averaging $72.03 per recipient.
What types of payments did Astellas Pharma US Inc make? ▾
7 categories of general payment make up Astellas Pharma US Inc's reported activity, including consulting, meals, travel, and similar types. The largest general-payment category was "Compensation for Services Other Than Consulting" at $4.0M, representing 37.7% of the company's reported total.
How does Astellas Pharma US Inc rank among pharmaceutical companies? ▾
By total payment amount, Astellas Pharma US Inc sits at #165 of 1,925 companies in the CMS Open Payments database for 2024.
What is the average payment size from Astellas Pharma US Inc? ▾
Astellas Pharma US Inc's 147,377 transactions to 147,377 recipients in 2024 averaged $72.03 per transaction.
Where does the payment data for Astellas Pharma US Inc come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Astellas Pharma US Inc's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.